ValenTx is a well-funded, early-stage medical device company developing a non-surgical therapy to treat obesity and obesity-related metabolic disorders. The company has successfully evaluated this technology in a series of human clinical trials and generated impressive initial results. ValenTx is aggressively expanding its organization to support continued product development and ongoing business objectives.